Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918651 | 0.85 | PRKCI (0.40) | AXLPRKCINOTUMJAK2JAK1 | |
| SCHEMBL12833213 | 0.81 | EGLN1 (0.38) | AURKATPX2NOTUMJAK2JAK1 | |
| SCHEMBL9918654 | 0.77 | NUDT1 (0.52) | AXLPRKCIJAK1JAK3 | |
| SCHEMBL1654705 | 0.72 | PDK1 (0.39) | AXLPRKCIAURKATPX2NOTUM | |
| SCHEMBL29588316 | 0.71 | AXL (0.56) | AXLPRKCINOTUMJAK2JAK1 | |
| SCHEMBL1154022 | 0.71 | AXL (0.56) | AXLPRKCINOTUMJAK2JAK1 | |
| SCHEMBL9918662 | 0.71 | PRKCI (0.55) | AXLPRKCIAURKAJAK2JAK1 | |
| SCHEMBL12684549 | 0.70 | PRKCI (0.42) | AXLPRKCIJAK2JAK1TYK2 | |
| SCHEMBL9918666 | 0.69 | JAK3 (0.38) | NOTUMJAK2JAK3 | |
| SCHEMBL3491733 | 0.68 | JAK3 (0.59) | NOTUMJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012106448-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | AXL 724/4885PRKCI 156/4885AURKA 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.